Wen Chi-jun, Zhu Ming-feng, Ren Wen-mei, Liu Xiao-ying, Qian Hong
Department of Pediatrics, Shanghai Second People's Hospital, Shanghai 200011, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 May;46(5):393-6.
To study the clinical efficacy of sublingual immunotherapy using standardized Dermatophagoides farinae extract for children with combined allergic rhinitis and asthma syndrome.
Fifty-two children, from 4 to 14 years of age, with mite-sensitive combined allergic rhinitis and asthma syndrome were treated sublingually with standardized Dermatophagoides farinae extract. The clinical efficacy was evaluated by monthly follow-up visits. After treatment for 1 or 2 years using the standardized Dermatophagoides farinae extract, the asthma and rhinitis symptom scores, medication scores and adverse reactions before and after treatment were evaluated. SPSS 17.0 software was used to analyze the data.
The allergic asthma symptom scores before treatment during the day were 3.22 ± 0.66 and at night 2.05 ± 0.57. After 1 year of treatment, the day and night scores (1.68 ± 0.61, 0.94 ± 0.32) respectively, were decreased significantly (q values were 15.25 and 13.78 respectively, all P < 0.01). After 2 years of treatment, the scores (0.61 ± 0.28, 0.43 ± 0.13) were also decreased significantly (q values were 10.29 and 6.07 respectively, all P < 0.01). The allergic rhinitis symptom scores and medication scores were 2.34 ± 0.59 and 3.09 ± 1.01 respectively before treatment and 1.21 ± 0.46 and 1.89 ± 0.64 after 1 year of treatment. The differences were significant (q values were 15.48 and 18.61 respectively, all P < 0.01). The allergic rhinitis symptom scores and medication scores were 1.02 ± 0.37 and 1.49 ± 0.38 after 2 years of treatment. There was no significant difference between 2 years of treatment and 1 year of treatment (q values were 2.53 and 2.78 respectively, all P > 0.05). There were no severe adverse events during the treatment, except for mild mouth cavity discomfort.
Sublingual immunotherapy using standardized Dermatophagoides farinae extract is safe and effective in the treatment of children with combined allergic rhinitis and asthma syndrome.
研究使用标准化粉尘螨提取物进行舌下免疫治疗对合并变应性鼻炎和哮喘综合征儿童的临床疗效。
选取52例4至14岁对螨敏感的合并变应性鼻炎和哮喘综合征儿童，采用标准化粉尘螨提取物进行舌下治疗。通过每月随访评估临床疗效。使用标准化粉尘螨提取物治疗1年或2年后，评估治疗前后的哮喘和鼻炎症状评分、用药评分及不良反应。采用SPSS 17.0软件进行数据分析。
治疗前变应性哮喘白天症状评分为3.22±0.66，夜间为2.05±0.57。治疗1年后，白天和夜间评分分别为(1.68±0.61，0.94±0.32)，均显著降低（q值分别为15.25和13.78，均P<0.01）。治疗2年后，评分(0.61±0.28，0.43±0.13)也显著降低（q值分别为10.29和6.07，均P<0.01）。治疗前变应性鼻炎症状评分和用药评分分别为2.34±0.59和3.09±1.01，治疗1年后分别为1.21±0.46和1.89±0.64。差异有统计学意义（q值分别为15.48和18.61，均P<0.01）。治疗2年后变应性鼻炎症状评分和用药评分分别为1.02±0.37和1.49±0.38。2年治疗与1年治疗之间无显著差异（q值分别为2.53和2.78，均P>0.05）。治疗期间除轻微口腔不适外，无严重不良事件发生。
使用标准化粉尘螨提取物进行舌下免疫治疗对合并变应性鼻炎和哮喘综合征的儿童安全有效。
Zotero 插件